Name

Celling Biosciences

Legal name

Celling Biosciences

Website

https://cellingbiosciences.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (33911), Surgical and Medical Instrument Manufacturing (339112), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Regenerative medicine devices
• Autologous cell therapy
• Bone marrow concentration
• Platelet-rich plasma systems
• Point-of-care processing

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device and Consumable Sales: Celling Biosciences generates revenue through the sale of medical devices and consumables for autologous cell therapy, including the ART BMC and ART PRP product families, bone marrow aspiration kits, injectable bone void fillers, and spinal hardware products. Products are sold directly to physicians and through distributor networks.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Celling Biosciences designs, manufactures, and sells point-of-care medical devices and consumables for autologous cellular therapy. Its core offering is the ART (Autologous Regenerative Therapies) family of bone marrow and platelet concentration systems, supplemented by bone marrow aspiration kits, Cell Probe 360 needles, Solum injectable bone void fillers, and a line of spinal hardware implants, all sold to physicians and healthcare providers.

Product overview

Celling Biosciences offers a comprehensive portfolio of point-of-care regenerative medicine products organized across three main categories: Tissue Collection (bone marrow aspiration kits), Tissue Concentration (ART PRP and ART BMC systems for concentrating platelets and bone marrow), and Tissue Delivery (Solum bone void fillers and spinal hardware). The ART product family is the company's core platform, featuring the only integrated ultra-filtration system on the market for processing bone marrow, peripheral blood, and growth factors. The portfolio also includes spinal hardware products developed in partnership with SpineSmith for biologics-minded spinal implants. The company has expanded through acquisitions including ThermiGen (aesthetics) and LinkSpine (spinal fusion systems), and recently announced the Cell Probe 360 aspiration needle pending release in 2024.

Differentiator

Problem solved

Functional benefit

Brands

• ART (Autologous Regenerative Therapies): Product portfolio designed for the optimal processing of tissue at the point of care to isolate certain cells for autologous cellular collection. Includes ART PRP Plus, ART PRP 2-Step, ART BMC Plus, and ART BMC systems.
• ThermiGen
• Cell Probe 360
• Solum

Products and services

• ART BMC Plus Bone marrow concentration system featuring an integrated ultra-filtration filter for processing proteins from platelet poor plasma, allowing physicians to select cell concentrate from user-defined portions of the centrifuged stack for the highest recovery of nucleated and progenitor cells at the point of care.
• ART BMC Single-use sterile bone marrow concentration device that processes autologous bone marrow aspirate into bone marrow concentrate at the point of care, functioning as a miniaturized laboratory with multiple ports to minimize sterile breaks.
• ART PRP Plus Platelet-rich plasma concentration system with integrated ultra-filtration that concentrates platelets using nanoporous fibers, reducing 60 mL of whole blood to 3-5 mL of concentrated platelet poor plasma at the point of care.
• ART PRP 2-Step Two-step platelet-rich plasma concentration system that processes autologous whole blood at the point of care and recovers the greatest percentage of platelets by allowing manual selection of platelet concentrate from user-defined portions of the centrifuged stack.
• Cell Probe 360 Patented bone marrow aspiration needle with an integrated valve system based on Dr. Philippe Hernigou's technique that simplifies the procedure by requiring only two syringes throughout, reducing procedure time and limiting sterile breaks.
• Large Volume Bone Marrow Aspiration Kit Bone marrow aspiration kit providing all components needed for large volume collection, including 11G aspiration needle, 18G blunt fill needle, syringes, mixing cup, and ACD-A anticoagulant.
• Small Volume Bone Marrow Aspiration Kit Bone marrow aspiration kit designed for small volume collection, including seven 10 mL syringes and ACD-A anticoagulant.
• Solum Flow Injectable bone void filler composed of an equal ratio of porous hydroxyapatite granules and porcine gelatin, combined at a 1:1 volume ratio with biological fluid, with viscosity that allows easy injection from a needle.
• Solum IV Synthetic extracellular matrix biomaterial with an interconnected pore architecture that supports cell adhesion, migration, and proliferation; when combined with bone marrow aspirate, forms a moldable 3D structure that acts as an in vivo bioreactor for bone growth.
• VisuALIF Two-piece modular lumbar interbody fusion device with modular plating options, anterior open face PEEK component, radiolucent and biocompatible design with radiopaque tantalum markers, and patented design for maximum graft placement.
• IN:C2 Two-piece modular cervical interbody fusion device with modular plating options, multiple screw placement and trajectory choices, and a locking snap-on face plate.
• Corticalink System Spinal fixation system featuring Quadlead thread design for optimal stability, with self-tapping and self-starting screws, available in 5.5 Corticalink Open System, 5.0 MIS Corticalink, and 5.0 Midline Corticalink variants.
• Facet Link Mini Facet joint stabilization system that provides robust spinal support and stability through a minimally invasive trans-articular screw approach.
• Cimplicity Cervical interbody spacer made of biocompatible, radiolucent polyether ether ketone (PEEK) with a large graft area designed to maximize fusion potential.

Quantifiable outcome

• The Hernigou aspiration method (basis for Cell Probe 360) obtains 300% more mesenchymal stem cells than traditional aspiration techniques
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• ThermiGencoreStrategic or Co-development Partner · 1 January 2019Celling Biosciences acquired ThermiGen in 2019, expanding into women's health and skin aesthetics markets. ThermiGen is known for its flagship product ThermiRF, which uses temperature to guide non-invasive and minimally-invasive procedures.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• SpineSmith Partners: SpineSmith is a partner that has co-developed spinal hardware products with Celling and operates directly in the same spinal fusion and biologics segment as Celling's VisuALIF, IN:C2, Corticalink, and Cimplicity devices.
• Emcyte Corporation: Emcyte is a direct competitor in point-of-care autologous PRP and bone marrow concentration systems, offering devices such as the Angel Concentrated Platelet Rich Plasma system that compete head-to-head with Celling's ART PRP and ART BMC families.
• Isto Biologics: Isto Biologics develops autologous and allogeneic orthobiologic solutions including bone marrow concentration devices and bone graft substitutes, directly overlapping with Celling's ART BMC systems and Solum bone void filler products.

Emerging players

• Regenexx: Regenexx is a regenerative medicine network that delivers autologous cell therapy procedures, including bone marrow concentrate treatments, to patients via affiliated physicians — directly comparable to Celling's clinical use cases in orthopedics and spine.
• LifeNet Health: LifeNet Health is a regenerative medicine organization offering allograft and cellular therapies used in orthopedics, spine, and wound care — comparable to Celling's regenerative and bone void filler portfolio, though with a different sourcing and distribution model.
• Cesca Therapeutics: Cesca Therapeutics develops autologous cell-based therapies and point-of-care cell processing technologies, making it a comparable emerging player in the autologous regenerative medicine category alongside Celling.

Broad incumbents

• Terumo BCT: Terumo BCT is a leading cell and blood component processing technology provider. While focused on apheresis and higher-volume cell processing, its technology and commercial reach overlap with Celling's point-of-care concentration space.
• Stryker: Stryker is a large diversified medtech player with deep orthopedic, spine, and surgical hardware franchises that overlap with Celling's spinal hardware (LinkSpine) and broader orthopedic cell therapy customers.
• Zimmer Biomet: Zimmer Biomet operates broadly across orthopedics and sports medicine and has invested in regenerative and autologous biologic offerings, making it a broad incumbent comparable to Celling's orthopedic and spine regenerative portfolio.
• Arthrex: Arthrex is a broad incumbent in orthopedic devices and biologics, offering PRP/BMAC preparation systems used across sports medicine, orthopedics, and spine — competing with Celling across multiple of the same specialties but as part of a much larger portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/cellingbio
• YouTubeyoutube.com/@CellingBiosciences
• LinkedInlinkedin.com/company/celling-biosciences
• Instagraminstagram.com/celling_biosciences/?hl=en

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celling Biosciences